Dec. 3 at 12:36 PM
$CRVO In the extension phase, participants who received a new batch of capsules and achieved target concentrations showed an average reduction of 16.7 pg/mL in plasma GFAP levels, compared to an increase of 5.8 pg/mL during placebo administration. The company also reported an increase in the 42/40 amyloid beta ratio and a trend toward reduced neurofilament light chain levels. The trial enrolled 159 participants with DLB at 43 sites in the United States, Great Britain, and the Netherlands. DLB is the second most common form of progressive dementia after Alzheimer's disease, with no approved treatments in the United States or the European Union. CervoMed plans to initiate a Phase 3 trial in the second half of 2026. The RewinD-LB study was funded primarily by a
$21.3 million grant from the National Institute on Aging.
